ATHN 9: Severe VWD Natural History Study

Recruiting in Palo Alto (17 mi)

+24 other locations

Overseen byAngela Weyand, MD

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: American Thrombosis and Hemostasis Network

No Placebo Group

Trial Summary

What is the purpose of this trial?

ATHN 9 is a natural history study to assess the safety of various Von Willebrand Factor (VWF) regimens for different indications (on-demand, surgery and prophylaxis) in adult and pediatric participants with clinically severe congenital VWD.

Eligibility Criteria

Inclusion Criteria

Participants with severe Von Willebrand Disease with Type 3 VWD or VWF:RCo, VWF:GPlbM or VWF:Ag ≤30% of pooled normal control plasma on more than one occasion;

Participants with clinically severe VWD as defined by VWF:RCo, VWF:GPlbM or VWF:Ag ≤40% of normal with severe bleeding phenotype defined as requiring recurrent use of factor concentrates;

Co-enrollment in the ATHNdataset.